39. (Once amended) A method according to claim 38 wherein the non-rodent mammal is a human.

40. (Once amended) A method according to claim 46 wherein the *Plasmodium* species is *Plasmodium falciparum*.

41. (Twice amended) A method according to claim 38 wherein the agent is administered by inhalation to increase systemic nitric oxide levels or nitric oxide effect.

42. (Once amended) A method according to claim 38 wherein the agent is a nitric oxide (NO) donor.

43. (Once amended) A method according to claim 38 wherein the agent results in the formation within the circulatory system of nitric oxide in the form of a compound of formula:

R-NO

Wherein R is an NO releasing, delivering or transferring moiety selected from the group consisting of an amino acid, peptide, polypeptide, protein, enzyme, amine, glycolipid, polysaccharide and a chemical derivative thereof.

Please cancel claim 44 without prejudice.

45. (Once amended) A method according to claim 38 wherein the agent is selected from the group consisting of cysteinylglycine, cysteine, cysteamine, lipoic acid, dithiothreitol, glutathione, L-arginine, penicillamine, N-acetyl-penicillamine, N-acetylcysteine, albumin, tissue plasminogen activator, streptokinase, a cytokine, an antagonist or agonist of a cytokine, interferon $(IFN)_{\alpha}$, IFN_{β}, IFN_{γ}, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), an interleukin (IL) 1 to IL13, hemoglobin and cathepsin B.